Psoriasis: Treatment and Pathogenesis

Background: Topical corticosteroids (TCS) remain the first-line treatment for atopic dermatitis (AD) and related inflammatory skin diseases, yet no standardized definition of response exists. This gap contributes to heterogeneity in clinical practice and complicates trial design. We therefore aimed to develop consensu…

• ÖZLEM SU KÜÇÜK

Background Early achievement of complete skin clearance (PASI100) is a key therapeutic goal in the management of moderate‐to‐severe psoriasis. Identifying predictors of early response to biologic therapy may improve treatment selection and optimize patient outcomes. Methods This retrospective cohort study included adu…

• ÖZLEM SU KÜÇÜK

OBJECTIVE: The kynurenine pathway(KP) of tryptophan catabolism is a major regulator of the immune response. Metabolites of this pathway may have protective or degenerative effects on the nervous system. Based on our recent studies, we tested the hypothesis that KP metabolites play a role in the pathogenesis of the lin…

• MUHİTTİN ABDULKADİR SERDAR

BACKGROUND: The randomized, phase 2 GALAXI 1 study evaluated efficacy and safety of guselkumab, a dual-acting IL-23p19 subunit inhibitor, in participants with moderately to severely active Crohn's disease. Efficacy and safety through 5 years are reported. METHODS: After completing the 48-week, treat-through GALAXI 1 m…

Multipl skleroz (MS), inflamasyon, demiyelinizasyon ve nörodejenerasyon ile seyreden kronik otoimmün bir santral sinir sistemi hastalığıdır. Hastalık modifiye edici tedavilere rağmen bazı hastalarda yüksek hastalık aktivitesi ve progresyon devam edebilmektedir. Bu durumlarda immünsupresif tedaviler, bağışıklık aracılı…

Objective: The development of psoriasis involves disrupted signaling interactions between immune components and keratinocytes, leading to a chronic autoimmune state characterized by sustained inflammatory responses and epidermal hyperplasia.This study aimed to elucidate the anti-inflammatory potential of loganin (LOG)…

Aim: Biologic treatments have become important for optimal disease control in patients with moderate to severe plaque psoriasis.The term "super response" is used to describe a faster and more sustained response to biologic treatment.This study aimed to determine the characteristics of non-superresponder (NSR) and supe…

Özet henüz yok.

Özet henüz yok.

Purpose: Psoriasis is a common chronic inflammatory skin disease characterized by recurrent, scaly plaques. IL-17 plays a central role in its pathogenesis, and Secukinumab—an anti-IL-17A monoclonal antibody—is widely used for treatment. Long non-coding RNAs (LncRNAs) regulate keratinocyte proliferation and immune resp…

Background: Psoriatic arthritis (PsA) is a complex inflammatory disease with significant musculoskeletal, dermatological, and comorbidity burden. Despite therapeutic advances, many patients remain difficult to treat (D2T). Conventional definitions often overlook distinctions between inflammatory and non-inflammatory d…

Objective: In recent years, the therapeutic use of Janus kinase (JAK) inhibitors in dermatology, particularly in the management of atopic dermatitis (AD), has expanded markedly. This bibliometric study aimed to characterize research themes, evaluate the scientific productivity of authors and countries, and identify em…